224 related articles for article (PubMed ID: 9673264)
41. Mucosal and systemic immune responses elicited by recombinant Lactococcus lactis expressing a fusion protein composed of pertussis toxin and filamentous hemagglutinin from Bordetella pertussis.
Torkashvand A; Bahrami F; Adib M; Ajdary S
Microb Pathog; 2018 Jul; 120():155-160. PubMed ID: 29738814
[TBL] [Abstract][Full Text] [Related]
42. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.
Boros CA; Hanlon M; Gold MS; Roberton DM
Vaccine; 2001 May; 19(25-26):3537-42. PubMed ID: 11348721
[TBL] [Abstract][Full Text] [Related]
43. Proliferative responses to purified and fractionated Bordetella pertussis antigens in mice immunized with whole-cell pertussis vaccine.
Petersen JW; Andersen P; Ibsen PH; Capiau C; Wachmann CH; Hasløv K; Heron I
Vaccine; 1993; 11(4):463-72. PubMed ID: 8470432
[TBL] [Abstract][Full Text] [Related]
44. Human T cell immunity against Bordetella pertussis analyzed at clonal level.
De Magistris MT; Rappuoli R; Tagliabue A
Ann Ist Super Sanita; 1991; 27(1):33-6. PubMed ID: 1683526
[TBL] [Abstract][Full Text] [Related]
45. Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers.
Littmann M; Hülsse C; Riffelmann M; Wirsing von König CH
Vaccine; 2008 May; 26(19):2344-9. PubMed ID: 18396360
[TBL] [Abstract][Full Text] [Related]
46. Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.
Cherry JD; Heininger U; Richards DM; Storsaeter J; Gustafsson L; Ljungman M; Hallander HO
Clin Vaccine Immunol; 2010 May; 17(5):741-7. PubMed ID: 20335431
[TBL] [Abstract][Full Text] [Related]
47. Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells.
van den Berg BM; Beekhuizen H; Mooi FR; van Furth R
Infect Immun; 1999 Mar; 67(3):1050-5. PubMed ID: 10024542
[TBL] [Abstract][Full Text] [Related]
48. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France.
Grimprel E; Bégué P; Anjak I; Njamkepo E; François P; Guiso N
Clin Diagn Lab Immunol; 1996 Jan; 3(1):93-7. PubMed ID: 8770511
[TBL] [Abstract][Full Text] [Related]
49. Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model.
Huh DH; Han SB; Shin HJ; Ahn DH; Choi GS; Kang KR; Kim BR; Kang JH
J Microbiol Immunol Infect; 2018 Dec; 51(6):732-739. PubMed ID: 28720318
[TBL] [Abstract][Full Text] [Related]
50. International collaborative study: evaluation of proposed International Reference Reagent of pertussis antiserum (mouse) 97/642.
Gaines Das R; Xing D; Rigsby P; Newland P; Corbel M
Biologicals; 2001 Jun; 29(2):137-48. PubMed ID: 11580218
[TBL] [Abstract][Full Text] [Related]
51. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa.
Podda A; Nencioni L; Marsili I; Peppoloni S; Volpini G; Donati D; Di Tommaso A; De Magistris MT; Rappuoli R
Vaccine; 1991 Oct; 9(10):741-5. PubMed ID: 1759492
[TBL] [Abstract][Full Text] [Related]
52. Distribution of pertussis antibodies among different age groups in Japan.
Konda T; Kamachi K; Iwaki M; Matsunaga Y
Vaccine; 2002 Mar; 20(13-14):1711-7. PubMed ID: 11906757
[TBL] [Abstract][Full Text] [Related]
53. Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role.
Alonso S; Reveneau N; Pethe K; Locht C
Infect Immun; 2002 Aug; 70(8):4142-7. PubMed ID: 12117922
[TBL] [Abstract][Full Text] [Related]
54. Pertactin-Negative and Filamentous Hemagglutinin-Negative Bordetella pertussis, Australia, 2013-2017.
Xu Z; Octavia S; Luu LDW; Payne M; Timms V; Tay CY; Keil AD; Sintchenko V; Guiso N; Lan R
Emerg Infect Dis; 2019 Jun; 25(6):1196-1199. PubMed ID: 31107218
[TBL] [Abstract][Full Text] [Related]
55. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers.
Berstad AKH; Holst J; Frøholm LO; Haugen IL; Wedege E; Oftung F; Haneberg B
J Med Microbiol; 2000 Feb; 49(2):157-163. PubMed ID: 10670566
[TBL] [Abstract][Full Text] [Related]
56. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
Storsaeter J; Hallander HO; Gustafsson L; Olin P
Vaccine; 1998 Dec; 16(20):1907-16. PubMed ID: 9796042
[TBL] [Abstract][Full Text] [Related]
57. Sero epidemiology of Bordetella pertussis immune responses in a healthy population in northern Greece.
Polyzou A; Pournaras S; Dafni U; Sofianou D; Christeli E; Patrinos S; Tsakris A
J Clin Lab Anal; 2004; 18(3):211-4. PubMed ID: 15103688
[TBL] [Abstract][Full Text] [Related]
58. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis.
McGuirk P; McCann C; Mills KH
J Exp Med; 2002 Jan; 195(2):221-31. PubMed ID: 11805149
[TBL] [Abstract][Full Text] [Related]
59. Pertussis specific cell-mediated immune responses ten years after acellular pertussis booster vaccination in young adults.
Gröndahl-Yli-Hannuksela K; Kauko L; Van Der Meeren O; Mertsola J; He Q
Vaccine; 2016 Jan; 34(3):341-9. PubMed ID: 26643932
[TBL] [Abstract][Full Text] [Related]
60. [Analysis of chosen parameters of immuno response in mice immunized with whole-cell or acellular pertussis vaccines and challenged with B. pertussis strains harbouring different ptxS1/prn allele genes combinations].
Gzyl A; Augustynowicz E; Zawadka M; Rabczenko D; Slusarczyk J
Med Dosw Mikrobiol; 2007; 59(2):137-47. PubMed ID: 17929411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
